Canada markets open in 5 hours 58 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
46.61-1.08 (-2.26%)
At close: 04:00PM EDT
46.50 -0.11 (-0.24%)
After hours: 07:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close47.69
Open47.56
Bid39.94 x 100
Ask46.72 x 200
Day's Range46.31 - 47.57
52 Week Range42.63 - 56.26
Volume1,662,059
Avg. Volume1,929,487
Market Cap118.154B
Beta (5Y Monthly)0.45
PE Ratio (TTM)20.35
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.04 (4.37%)
Ex-Dividend DateMay 09, 2024
1y Target EstN/A
  • Reuters

    UPDATE 2-Sanofi profit slips on generic competition and currency effects

    Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

  • Reuters

    Sanofi profit slips on generic competition and currency effects

    (Reuters) -Sanofi's first-quarter operating income fell 14.7% as currency effects and cheap competition to its multiple sclerosis drug Aubagio outweighed rising sales of anti-inflammatory drug Dupixent, the French drugmaker said on Thursday. Operating income adjusted for one-offs slipped to 2.84 billion euros ($3.04 billion), a touch above the 2.79 billion euros expected by analysts in a poll on Sanofi's website. The company reiterated that it expects 2024 adjusted earnings per share (EPS) to slip by a low single-digit percentage, excluding currency swings, citing higher taxes and an increase in development expenditure.

  • Zacks

    What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

    Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.